Ultragenyx

Crysvita sales push Ultragenyx ahead for the quarter
BioCentury
Fri, 08/2/19 - 12:24 am
Ultragenyx
Crysvita
earnings
The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate
Yahoo/Benzinga
Sun, 07/28/19 - 11:48 pm
biotech
earnings
Immunic
Alkermes
Conatus
Aevi Genomic
Tricida
Curis
Ultragenyx
Leap Therapeutics
Cidara Therapeutics
Akcea
Spark Therapeutics
Eli Lilly
AnaptysBio
clinical trials
Ultragenyx close to learning whether gene therapy gamble will pay off
Biopharma Dive
Fri, 07/19/19 - 12:51 pm
Ultragenyx
Dimension Therapeutics
gene therapy
DTX-301
DTX-401
A former failure in PhII, the go-go FDA says it’s ready to consider an accelerated shortcut for Ultragenyx’s UX007
Endpoints
Wed, 08/29/18 - 10:41 am
Ultragenyx
UX007
FDA
LC-FAOD
After FDA Approves Bone Disease Drug, Ultragenyx Sets $200K Price
Xconomy
Tue, 04/17/18 - 09:55 pm
Ultragenyx
FDA
X-linked hypophosphatemia
What’s the big hurry Novartis? Pharma giant scores a PRV shortcut for $130M
Endpoints
Mon, 12/18/17 - 10:02 am
Novartis
priority review vouchers
Ultragenyx
UltraGenyx wins first drug approval, valuable PRV
BioPharma Dive
Thu, 11/16/17 - 07:17 pm
Ultragenyx
FDA
priority review
Mepsevii
Sly Syndrome
Bidding war erupts over Dimension’s gene therapy pipeline as Ultragenyx counters Regenxbio deal
Endpoints
Mon, 09/18/17 - 09:26 am
Dimension Therapeutics
Ultragenyx
Regenxbio
gene therapy
R&D
Ultragenyx shelves genetic disease drug after trial failure
BioPharma Dive
Wed, 08/23/17 - 10:08 pm
Ultragenyx
clinical trials
Ace-ER
Positive results help Ultragenyx recover after prior failure
BioPharma Dive
Thu, 04/20/17 - 09:51 am
Ultragenyx
KRN23
burosumab
hypophosphatemia
Ultragenyx shares tumble lower after rare disease drug fails PhII trial
Endpoints
Thu, 03/23/17 - 09:24 am
Ultragenyx
clinical trials
UX007
Glut1 DS
These 15 Biotech Companies Could Be Takeover Targets
Barron's
Wed, 06/29/16 - 12:56 pm
biotech
M&A
Alder Biopharmaceuticals
Biomarin
Coherus Biosciences
Intercept Pharma
Ultragenyx
Seattle Genetics
Adamas Pharmaceuticals
Alexion
Clovis Oncology
Corbus Pharmaceuticals
Incyte
Prothena
Puma Biotechnology
Tesaro
Versartis
8 Major Biopharma Events Coming Later in 2016 and in 2017
24/7 Wall St
Tue, 03/29/16 - 10:33 pm
Vertex Pharmaceuticals
VX-661
cystic fibrosis
Incyte
ruxolitinib
colorectal cancer
breast cancer
Ultragenyx
KRN23
osteomalacia
GW Pharma
Epidiolex
Puma Biotechnology
neratinib
Celator Pharmaceuticals
Vyxeos
Biocryst
OPuS-2
BCX7353
HAE
Galena Biopharma
NeuVax
trastuzumab
8 Biotech Stocks That Have a ‘Greater Probability’ of Being Acquired
Barron's
Tue, 03/29/16 - 12:24 pm
biotech
M&A
Ardelyx
Ophthotech
Medivation
Puma Biotechnology
Ultragenyx
Portola Pharmaceuticals
Versartis
Relypsa
Sanofi scouts for rare disease buyouts as Shire bears down on the field
Fierce Biotech
Tue, 03/1/16 - 09:37 am
Sanofi
Shire
M&A
R&D
Biomarin
Ionis Pharmaceuticals
Ultragenyx
Shire’s Next Targets Could Be on This List: Real M&A
Bloomberg
Wed, 01/14/15 - 10:00 am
Shire
M&A
PTC Therapeutics
SynaGeva BioPharma
Retrophin
Ultragenyx
Vertex Pharmaceuticals
Biomarin
19 Lesser-Known Biotech Stocks With Robust Drug Pipelines
Yahoo/Benzinga
Wed, 12/31/14 - 10:37 am
biotech
Threshold Pharmaceuticals
Acceleron
Spectrum Pharmaceuticals
Ultragenyx
Argos Therapeutics
OncoMed
Peregrine Pharmaceuticals
Incyte
Calithera
Array Biopharma
Theravance
Puma Biotechnology
CTI BioPharma
Orexigen
Enanta Pharmaceuticals
Sucampo
Exelixis
Cubist Pharmaceuticals
United Therapeutics
Ultragenyx Reports Data from Sialic Acid Deficiency Study
Yahoo/Zacks
Sat, 10/18/14 - 10:03 am
Ultragenyx
SA-ER
hereditary inclusion body myopathy
2014's most successful biotech IPOs
Fierce Biotech
Mon, 10/13/14 - 08:03 am
IPOs
biotech
Ultragenyx
ZS Pharma
Auspex Pharmaceuticals
Avalanche Biotechnologies
SAGE Therapeutics
Kite Pharma
Otonomy
Zafgen
ProQR
Radius Health
3 Biotech Stocks Breaking Out on Big Volume
TheStreet.com
Mon, 07/21/14 - 10:36 am
Ultragenyx
Bluebird Bio
Immunogen

Pages